Sequencing Efficacy Safety Dosing and Administration Expert Conversations Previous Next Read more Previous Play Next Uptake of subsequent therapy in LUX-Lung 3, 6 and 7 12/04/2024 | Author: Boehringer Ingelheim Document ID: PC-MY-102817 Sequencing Sequential treatment afatinib RWDRI||Real-World Effectiveness of Sequential GIOTRIF® & osimertinib - Data from GIOTAG and RESET studies SEREAL||GIOTRIF® followed by 3rd generation TKI in GioSwing Sequential Cohort (Combined Analysis of Two Global Non-Interventional Studies) Totality Outcome of Afatinib (GIOTRIF®) Sequential Treatment in Patients with EGFRM+ NSCLC (CNS cohort) GIOTRIF® followed by 3rd generation TKI in UpSwing Sequential Cohort MYSEREAL||GIOTRIF® followed by 3rd generation TKI in RESET study SEREAL||Japan real world evidence supports sequential treatment with the use of upfront 2nd generation TKI SEREAL||GioTag, the 1st global study to show feasibility of sequential therapy with GIOTRIF® followed by osimertinib SEREAL||Post-hoc analyses from LUX-Lung trials: GIOTRIF(R) followed by 3rd generation TKI SEREAL||Uptake of subsequent therapy in LUX-Lung 3, 6 and 7 Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: final analysis of the GioTag study Totality Outcome of Afatinib (GIOTRIF®) Sequential Treatment in Patients with EGFRM+ NSCLC RELATED CONTENT Read more PDF Japan real world evidence supports sequential treatment with the use of upfront 2nd generation TKI Download Opens in new tab Read more PDF GioTag, the 1st global study to show feasibility of sequential therapy with GIOTRIF® followed by osimertinib Download Opens in new tab Read more PDF Post-hoc analyses from LUX-Lung trials: GIOTRIF(R) followed by 3rd generation TKI Download Opens in new tab Read more PDF Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: final analysis of the GioTag study Download Opens in new tab Read more PDF Totality Outcome of Afatinib (GIOTRIF®) Sequential Treatment in Patients with EGFRM+ NSCLC Download Opens in new tab Home Oncology Giotrif Sequencing SEREAL||Uptake of subsequent therapy in LUX-Lung 3, 6 and 7
Read more PDF Japan real world evidence supports sequential treatment with the use of upfront 2nd generation TKI Download Opens in new tab
Read more PDF GioTag, the 1st global study to show feasibility of sequential therapy with GIOTRIF® followed by osimertinib Download Opens in new tab
Read more PDF Post-hoc analyses from LUX-Lung trials: GIOTRIF(R) followed by 3rd generation TKI Download Opens in new tab
Read more PDF Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: final analysis of the GioTag study Download Opens in new tab
Read more PDF Totality Outcome of Afatinib (GIOTRIF®) Sequential Treatment in Patients with EGFRM+ NSCLC Download Opens in new tab